We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has approved their PARP inhibitor Lynparza for a broader ovarian cancer population.
Lynparza in combination with Roche’s (RHHBY - Free Report) Avastin has been approved as a maintenance treatment for first-line advanced ovarian cancer in women who have an HRD-positive tumor. About one in two women with advanced ovarian cancer has an HRD-positive tumor.
Meanwhile, the FDA also simultaneously approved Myriad Genetics’ (MYGN - Free Report) myChoiceCDx test for use as a companion diagnostic test to identify patients with HRD positive ovarian cancer who will likely respond to Lynparza treatment.
The approval of Lynparza for the expanded ovarian cancer group was based on data from the phase III PAOLA-1 study. Data from the PAOLA-1 study showed that Lynparza when added to Avastin as a first-line maintenance treatment reduced the risk of disease progression or death by 67% in patients with HRD-positive advanced ovarian cancer. When Lynparza was added to Avastin to treat the patient group, it improved progression-free survival (PFS) to a median of 37.2 months versus 17.7 months with Avastin. Similar label expansion applications are under review in the EU, Japan and other countries
Lynparza is presently approved as first-line maintenance treatment for BRCAm advanced ovarian cancer, following response to platinum-based chemotherapy based on data from the phase III SOLO-1 study. With the approval for the first-line maintenance indication based on PAOLA-1 study, Lynparza can be prescribed to a much wider ovarian cancer patient population including those who do not have the BRCA mutation. This can significantly increase the market for the drug.
This year so far, AstraZeneca’s shares have risen 8.2% against a decrease of 2.8% for the industry
Lynparza, presently approved in three tumor types— ovarian, breast and pancreatic— is being evaluated as a monotherapy and in combination across multiple tumor types. Importantly, it is under priority review in the United States for metastatic castration-resistant prostate cancer (with HRR genetic mutations). It is also being evaluated as a potential adjuvant treatment for germline BRCA-mutated high-risk HER2-negative primary breast cancer in the phase III OlympiA study.
Lynparza, which is being jointly developed and commercialized by AstraZeneca and Merck, generated product sales of $397 million for AstraZeneca in the first quarter of 2020, and alliance revenues of $145 million for Merck. AstraZeneca will receive $100 million in milestone payment from Merck, following the latest approval for HRD-positive advanced ovarian cancer
In a separate press release, AstraZeneca announced that the FDA granted Breakthrough Therapy Designation (BTD) to antibody drug conjugate Enhertu for HER2-positive metastatic gastric cancer. The BTD was based on data from the registration phase II DESTINY-Gastric01 study. Enhertu was approved by the FDA in December last year for metastatic breast cancer. AstraZeneca acquired joint development and commercialization rights to this promising cancer candidate from Japan’s Daiichi Sankyo in April last year.
AstraZeneca also announced that it has completed the previously announced deal to recover the global rights to a mid-stage candidate brazikumab from Allergan. Brazikumab is a monoclonal antibody, which is being developed for Crohn’s disease (CD) and ulcerative colitis. Allergan divested brazikumab in connection with its now closed merger with AbbVie. AstraZeneca and Allergan had a license agreement for brazikumab, which is now terminated and all rights to brazikumab are back with AstraZeneca.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
AstraZeneca (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has approved their PARP inhibitor Lynparza for a broader ovarian cancer population.
Lynparza in combination with Roche’s (RHHBY - Free Report) Avastin has been approved as a maintenance treatment for first-line advanced ovarian cancer in women who have an HRD-positive tumor. About one in two women with advanced ovarian cancer has an HRD-positive tumor.
Meanwhile, the FDA also simultaneously approved Myriad Genetics’ (MYGN - Free Report) myChoiceCDx test for use as a companion diagnostic test to identify patients with HRD positive ovarian cancer who will likely respond to Lynparza treatment.
The approval of Lynparza for the expanded ovarian cancer group was based on data from the phase III PAOLA-1 study. Data from the PAOLA-1 study showed that Lynparza when added to Avastin as a first-line maintenance treatment reduced the risk of disease progression or death by 67% in patients with HRD-positive advanced ovarian cancer. When Lynparza was added to Avastin to treat the patient group, it improved progression-free survival (PFS) to a median of 37.2 months versus 17.7 months with Avastin. Similar label expansion applications are under review in the EU, Japan and other countries
Lynparza is presently approved as first-line maintenance treatment for BRCAm advanced ovarian cancer, following response to platinum-based chemotherapy based on data from the phase III SOLO-1 study. With the approval for the first-line maintenance indication based on PAOLA-1 study, Lynparza can be prescribed to a much wider ovarian cancer patient population including those who do not have the BRCA mutation. This can significantly increase the market for the drug.
This year so far, AstraZeneca’s shares have risen 8.2% against a decrease of 2.8% for the industry
Lynparza, presently approved in three tumor types— ovarian, breast and pancreatic— is being evaluated as a monotherapy and in combination across multiple tumor types. Importantly, it is under priority review in the United States for metastatic castration-resistant prostate cancer (with HRR genetic mutations). It is also being evaluated as a potential adjuvant treatment for germline BRCA-mutated high-risk HER2-negative primary breast cancer in the phase III OlympiA study.
Lynparza, which is being jointly developed and commercialized by AstraZeneca and Merck, generated product sales of $397 million for AstraZeneca in the first quarter of 2020, and alliance revenues of $145 million for Merck. AstraZeneca will receive $100 million in milestone payment from Merck, following the latest approval for HRD-positive advanced ovarian cancer
In a separate press release, AstraZeneca announced that the FDA granted Breakthrough Therapy Designation (BTD) to antibody drug conjugate Enhertu for HER2-positive metastatic gastric cancer. The BTD was based on data from the registration phase II DESTINY-Gastric01 study. Enhertu was approved by the FDA in December last year for metastatic breast cancer. AstraZeneca acquired joint development and commercialization rights to this promising cancer candidate from Japan’s Daiichi Sankyo in April last year.
AstraZeneca also announced that it has completed the previously announced deal to recover the global rights to a mid-stage candidate brazikumab from Allergan. Brazikumab is a monoclonal antibody, which is being developed for Crohn’s disease (CD) and ulcerative colitis. Allergan divested brazikumab in connection with its now closed merger with AbbVie. AstraZeneca and Allergan had a license agreement for brazikumab, which is now terminated and all rights to brazikumab are back with AstraZeneca.
AstraZeneca currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>